- Home
- RFL vs MREO Comparison
RFL vs MREO Comparison
Compare RFL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFL | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 59.2M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RFL | MREO |
|---|---|---|
| Price | $1.27 | $0.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 57.5K | ★ 4.2M |
| Earning Date | 03-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $0.20 |
| 52 Week High | $3.19 | $2.94 |
Technical Indicators
Market Signals| Indicator | RFL | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 37.72 |
| Support Level | $1.17 | $0.35 |
| Resistance Level | $1.28 | $0.44 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 61.54 | 62.96 |
Price Performance
Historical ComparisonAbout RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).